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Abstract
Hepatocellular carcinoma (HCC) is a hypervascular highly angiogenic tumor usually associated with liver cirrhosis.
Vascular endothelial growth factor plays a critical role in vascular development in HCC. In contrast to the treatment
of early-stage HCC, the treatment options for advanced HCC are limited and prognosis is often poor, which con-
tributes to this tumor type being the third leading cause of cancer-related deaths worldwide. Metronomic chemo-
therapy, which was originally designed to inhibit angiogenesis, involves low-dose chemotherapeutic agents
administered in a frequent regular schedule with no prolonged breaks and minimizes severe toxicities. We
reviewed the potential effects and impact of metronomic chemotherapy in preclinical studies with HCC models
and in patients with advanced HCC, especially when combined with a molecular targeted agent. Metronomic
chemotherapy involves multiple mechanisms that include antiangiogenesis and antivasculogenesis, immune
stimulation by reducing regulatory T cells and inducing dendritic cell maturation, and possibly some direct tumor
cell targeting effects, including the cancer stem cell subpopulation. The total number of preclinical studies with
HCC models shows impressive results using metronomic chemotherapy-based protocols, especially in conjunc-
tion with molecular targeted agents. Four clinical trials and two case reports evaluating metronomic chemotherapy
for HCC indicate it to be a safe and potentially useful treatment for HCC. Several preclinical and clinical HCC stud-
ies suggest that metronomic chemotherapy may become an alternative type of chemotherapy for advanced
unresectable HCC and postsurgical adjuvant treatment of HCC.
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Introduction
Systemic chemotherapy with cytotoxic agents remains the most
common systemic therapy to treat patients with metastatic disease.
Most anticancer agents are designed to inhibit growth or kill rapidly
dividing tumor cells. These drugs are usually administered at the
highest doses possible to induce the maximum therapeutic effect;
this is referred to as maximum tolerated dose (MTD) therapy
[1,2]. However, administration of anticancer agents at MTD requires
prolonged breaks between cycles of the therapy to allow recovery
from the induced adverse side effects in different tissues and
organs. These gaps in chemotherapy can allow or facilitate tumor
regrowth including growth of clones resistant to the therapy. The
regrowth of tumor or drug resistance clones during such gaps can
prevent or compromise improvement of overall survival of patients
with advanced cancer even when the first cycle of MTD therapy is
effective [1,3–6].
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A new concept of anticancer treatment that targets the tumor vas-
culature was first proposed by Folkman in 1971 [7]. This treatment
concept is based on the indispensable role of the vasculature in tumor
growth [8,9]. Antiangiogenic therapy has been investigated exten-
sively in both preclinical and clinical studies [10,11]. In 1991, Kerbel
[12] suggested that some conventional cytotoxic anticancer agents can
suppress vascular development in tumors based on the immature and
proliferative nature of endothelial cells present in the neovasculature.
Klement et al. [13] and Browder et al. [14] reported that frequent
repetitive low doses of chemotherapy drugs such as cyclophosphamide
or vinblastine could markedly suppress tumor growth. Hanahan et al.
coined the term metronomic therapy to describe this type of thera-
peutic schedule [15]. Metronomic therapy generally consists of the
continuous administration of low-dose chemotherapeutic agents
without extended intervals [2]. It was originally designed with the
intention to inhibit tumor growth by antiangiogenic mechanisms,
though other mechanisms can contribute to its antitumor efficacy
as described below, and is usually associated with much less severe
acute toxicities compared to conventional MTD chemotherapy [16].
So, recently, metronomic chemotherapy has been investigated in pedi-
atric oncology [17]. Most new cancer cases and deaths now occur in
low-income andmiddle-income countries [18]. As metronomic chemo-
therapy is a low-cost, well-tolerated, and easy-to-access treatment, it will
be an attractive therapeutic option in resource-limited countries [19].
Hepatocellular carcinoma (HCC) is the sixth most common solid
tumor and the third leading cause of cancer-related death globally
[20,21]. Although the major blood supply to HCC is the portal veins
at the early stage of hepatocarcinogenesis, the main supply ultimately
is provided by neoarteries that develop in parallel with tumor growth
[22–24]. For advanced HCC, such as Barcelona Clinic Liver Cancer
(BCLC) stage C, classical chemotherapy is sometimes selected [25].
However, HCC is usually associated with liver cirrhosis, and thus
aggressive chemotherapy can cause severe side effects [26]. Unfortu-
nately, the prognosis of patients with advanced HCC is usually poor
even in those treated with sorafenib [27,28]. To improve the thera-
peutic efficacy and prognosis of patients with advanced HCC, new
strategies are clearly needed.
In this review, we evaluate the potential effects and impact of met-
ronomic chemotherapy in patients with advanced HCC, especially
when combined with a molecular targeted agent such as sorafenib.
Treatment for Advanced HCC
The development of sophisticated diagnostic modalities, such as
computed tomography, magnetic resonance imaging, and abdominal
ultrasonography, has allowed early diagnosis of HCC [29–32].
Patients with small HCCs are usually treated by surgical resection,
liver transplantation, percutaneous ethanol injection therapy, micro-
wave coagulation therapy, or percutaneous radiofrequency ablation
[33]. The prognosis of patients with small HCCs has improved fol-
lowing the application of these therapeutic modalities [33].
Treatment of advanced HCC includes transhepatic arterial chemo-
embolization, transhepatic arterial infusion chemotherapy, systemic
chemotherapy, hormonal therapy, and immunotherapy [32,34–37].
However, only transhepatic arterial chemoembolization has been
confirmed to improve long-term survival in BCLC stage B [38–41].
In large randomized trials, the median survival time (MST) of patients
treated with doxorubicin were 6.8 and 7.4 months, respectively [42,43].
The MST of patients treated with PIAF regimen (cisplatin, interferon,
doxorubicin, and fluorouracil) and FOLFOX4 regimen (oxaliplatin and
fluorouracil) was 8.7 and 6.4 months, respectively. In three double-
blinded, placebo-controlled trials, no survival benefit of tamox-
ifen was confirmed [44–46]. In several small studies, the MST
of patients with HCC treated with capecitabine and gemcitabine
was 10.1 and 6.9 months, respectively [47,48]. Other drugs such
as cisplatin, 5-fluorouracil (5-FU), mitoxantrone, etoposide, pacli-
taxel, irinotecan, and fludarabine have also failed to demonstrate
meaningful activity [49–55]. Despite maximum effort by many in-
vestigators, any definitive evidences that systemic chemotherapy is
effective for advanced HCC have not been provided [56]. Sorafenib is
an orally active multi-kinase inhibitor that targets vascular endothelial
growth factor receptor 2 (VEGFR-2) and PDGF receptors, among
others, and also blocks tumor cell proliferation by targeting the Raf/
mitogen-activated protein kinase kinase (MEK)/extracellular signal-
regulated kinases (ERKs) signaling pathway by virtue of its targeting
the intracellular threonine kinase Raf [57–59]. The efficacy of sorafenib
for advanced HCC was confirmed for the first time in the phase III
SHARP trial (MST; 10.7months) and theAsian-Pacific phase III region
trial (MST; 6.5 months) [27,28]. For advanced unresectable HCCwith
vascular invasion or extrahepatic metastasis (BCLC stage C), adminis-
tration of sorafenib is now recommended worldwide [1,60,61]. Several
trials with molecular target agents are underway. In the phase III
trial, the MST of brivanib was 9.5 months and that of sorafenib was
9.9 months. In another phase III trial, the MST of linifanib and
sorafenib was 9.1 and 9.8months, respectively. In combination therapy,
sorafenib and erlotinib (MST; 9.5 months) failed to prove the survival
benefit comparing with sorafenib alone (MST; 8.5 months). Any other
molecular target agents fail to surpass the efficacy of sorafenib so far.
Due to the associated liver cirrhosis, patients with HCC sometimes
develop severe side effects during conventional MTD chemotherapy,
as noted above. Sincemetronomic chemotherapy is less toxic and,more-
over, inhibits tumor growth through antiangiogenic mechanisms, this
new therapeutic strategy using certain conventional chemotherapeutic
drugs could be suitable for the treatment of advanced HCC.
Metronomic Chemotherapy
Preclinical Studies
The first preclinical studies of metronomic chemotherapy came
from the laboratories of Folkman and Kerbel [14]. To date, there
are more than 300 papers published on the preclinical effects of met-
ronomic chemotherapy, as listed in PubMed. These reports describe
the therapeutic efficacy of metronomic chemotherapy against at least
18 different types of cancers in the gastrointestinal tract, respiratory
system, blood, brain, skin, and genitourinary systems. The most fre-
quently selected anticancer drug for preclinical metronomic chemo-
therapy studies is cyclophosphamide. One interesting aspect of some
of these studies is the potent antitumor efficacy of metronomic chemo-
therapy regimens in models of advanced metastatic cancer especially
when combined with a targeted antiangiogenic drug which itself has
minimal activity in this setting [62,63].
The main antitumor effects caused by metronomic chemotherapy
are thought to be inhibition of tumor-associated vascular development
and stimulation of immunity rather than direct cytotoxic effects on
tumor cells (Figure 1) [12,64–66]. However, intriguingly, some recent
reports have implicated direct targeting of cancer stem cells as a possible
mechanism of metronomic cyclophosphamide [67], in contrast to
MTD cyclophosphamide that does not target this subpopulation
[68]. In the following section, we discuss recent information regarding
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mechanisms of metronomic chemotherapy, especially inhibition of vas-
cular development and stimulation of immunity mediated by metro-
nomic chemotherapy.
Inhibition of tumor angiogenesis/vascular development.
Direct cytotoxicity or inhibition of endothelial cell pro-
liferation. Many conventional cytotoxic chemotherapeutic
agents, such as cyclophosphamide, vinblastine, paclitaxel, docetaxel,
tegafur/uracil (UFT), and tegafur/gimeracil/oteracil potassium (S-1),
have antiangiogenic effects [69–75]. S-1 is composed of three com-
pounds, namely, tegafur, gimeracil, and oteracil. UFT and S-1 decrease
thymidine phosphorylase that is also called platelet-derived endothelial
growth factor. The effect of UFT and S-1 seems to induce the anti-
angiogenic effect. The activated endothelial cells of newly formed blood
capillaries are highly and selectively sensitive in vitro to very low con-
centrations of many conventional cytotoxic anticancer agents [76–81].
The antiangiogenic effects of conventional cytotoxic anticancer drugs
seem to be optimized by administration of smaller doses without long
breaks for prolonged periods [12].
Up-regulation of endogenous antiangiogenic factors and down-
regulation of endogenous angiogenic factors. Angiogenesis is
thought to be switched off or downregulated when levels of endog-
enous antiangiogenic factors such as thrombospondin-1 (TSP-1) and
angiostatin exceed those of angiogenic factors such as VEGF and
basic fibroblast growth factor (bFGF) [82]. Bocci et al. [83,84] reported
that protracted exposure of endothelial cells in vitro to low concen-
trations of various anticancer chemotherapeutic agents and ceramide
analog caused marked induction of gene and protein expression of
TSP-1. A number of other groups have reported up-regulation of cir-
culating levels of TSP-1 in mice or patients exposed to metronomic
chemotherapy [85]. TSP-1, a component of the extracellular matrix
produced by endothelial cells, tumor cells, and infiltrating stromal cells,
seems to act by binding to CD36 expressed on the cell membrane of
endothelial cells [86–88]. TSP-1 also binds to VEGF and sequesters its
angiogenic activity [89]. Hypoxia-inducible factor 1 (HIF-1) regulates
the expression of angiogenic factors such as VEGF, bFGF, and stromal
cell–derived factor 1 (SDF-1). Continuous administration of low-dose
topotecan was reported to decrease the expression of HIF-1α [34],
VEGF, and SDF-1 [90]. Administration of low-dose anthracycline
chemotherapeutic agents also inhibited HIF-1 transcription and the
expression of VEGF and SDF-1 [91]. VEGF is the major factor in
angiogenesis/vascular development in many tumors [92,93]. A decrease
in serum VEGF levels was observed in patients with advanced breast
cancer treated with metronomic cyclophosphamide [94]. In addition,
metronomic chemotherapy with weekly platinum and daily etoposide
administration in patients with non–small cell lung cancer resulted in a
decrease in VEGF level during treatment [95].
Inhibition of vasculogenesis by reducing the number and viability
of circulating endothelial progenitor cells. Vascular development in
tumor tissues consists of angiogenesis and vasculogenesis. Vasculo-
genesis is generally defined as the contribution to the formation of
new blood vessels by circulating bone marrow–derived cells, possibly
including endothelial progenitor cells (EPCs) [96,97]. Accumulating
evidence suggests that circulating bone marrow–derived EPCs migrate
into tumor tissues to support vascular formation and tumor growth
[98,99]. In addition, local release of VEGF and SDF-1 induce the
migration of EPCs to tumor tissues through VEGFRs and CXCR4
on the cell surfaces of EPCs [100].
Bertolini et al. [101] reported that the administration of MTD
cyclophosphamide induced a robust EPC mobilization a few days
after the end of treatment in tumor-bearing mice bearing human
lymphoma cells. In marked contrast, metronomic chemotherapy of
cyclophosphamide, using lower doses given daily, was associated with
consistent decreases in the numbers and viability of EPCs, with a
much more durable and marked inhibition of tumor growth [101].
Stimulation of Immunity
Metronomic chemotherapy with certain chemotherapeutic agents
can stimulate the immune response by reducing regulatory T (Treg)
cells and inducing dendritic cell maturation [65,66,102]. Treg cells
are CD4+CD25+ lymphocytes known to accumulate in variety of
cancers [103]. Increased frequency of Treg cells correlate with tumor
progression and lack of treatment response [103]. Metronomic chemo-
therapy with cyclophosphamide and temozolomide was shown to
increase the antitumor immune responses by suppressing the number
and activity of Treg cells and also by increasing lymphocyte prolifera-
tion and memory T cells [65,66,104–106]. The reduction in Treg cell
number was specific, and the treatment had no effects on other types
of lymphocytes [106]. This effect was specific for metronomic chemo-
therapy. However, conventional MTD or high-dose chemotherapy can
result in depletion of all types of lymphocytes. Reduction of Treg
cells by metronomic chemotherapy restored the antitumor immune
response by recovering the activity of both tumor-specific (cytotoxic
T lymphocytes and helper T cells) and tumor-nonspecific effect cells
(natural killer and natural killer T cells) [106]. Other immunostimula-
tory effects of metronomic chemotherapy have been proposed recently.
Figure 1. Mechanisms of action of metronomic chemotherapy.
The beneficial effects of metronomic chemotherapy are mediated
through inhibition of vasculogenesis and angiogenesis, activation
of immunity, and probably direct inhibition of tumor cell prolifera-
tion. Inhibition of vasculogenesis and angiogenesis plays a critical
role in metronomic chemotherapy. Inhibition of vasculogenesis
and angiogenesis includes direct inhibition of endothelial cell pro-
liferation, up-regulation of endogenous angiogenic inhibitor such
as TSP-1, suppression of HIF-1α, and inhibition of EPC homing
in tumor tissues. Metronomic chemotherapy also stimulates anti-
tumor immunity by reducing the number of Treg cells and possibly
inducing dendritic cell maturation.
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As an example, Tanaka et al. [102] reported that vinblastine, paclitaxel,
and etoposide promoted dendritic cell maturation at nontoxic concen-
trations. They also found that local injection of low-dose vinblastine
induced the maturation of tumor-infiltrating dendritic cells and
stimulated antitumor immune responses in vivo [107]. However, the
involvement of dendritic cell maturation by metronomic chemotherapy
needs to be further investigated and confirmed. Preclinical studies using
immunodeficient mice have shown that metronomic chemotherapy
can result in marked tumor growth suppression. Such results indicate
that the involvement of the immune system in metronomic chemo-
therapy is not necessarily critical [108,109]. Nevertheless, it is interest-
ing to consider the potential benefits of combining metronomic
chemotherapy with immunotherapeutic treatments, e.g., tumor
vaccines [110].
Metronomic Chemotherapy: Studies Using
HCC Models
The potential efficacy of various metronomic chemotherapy protocols
using cyclophosphamide, UFT, cisplatin, and doxorubicin have been
investigated in animal models of HCC [111,112], as summarized in
Table 1. Park et al. [113] reported that metronomic chemotherapy with
cyclophosphamide inhibited HCC growth and prolonged survival
without inducing major toxicities using a rat HCC model with accom-
panying liver cirrhosis. Tang et al. [111] reported that single or doublet
metronomic chemotherapy using cyclophosphamide, UFT, and/or
doxorubicin without any added antiangiogenic agents did not have sur-
vival benefits. In contrast, they reported a significant improvement of
overall survival in animals that received various combinations of met-
ronomic chemotherapeutic regimens with DC101, an anti–VEGFR-2
targeting antibody that potently inhibits angiogenesis. They also
reported that metronomic chemotherapy with metronomic UFT and
sorafenib delayed the onset of tumor progression (i.e., delayed develop-
ment of resistance to chemotherapy) [114]. Zhou et al. [115] also
reported that metronomic doxorubicin in combination with bevacizu-
mab had a profound effect on tumor growth inhibition and survival of
HCC xenograft model. The appearance of resistance to molecular
targeted agents, such as sorafenib, is an inevitable problem in the treat-
ment of advanced unresectable HCC. Thus, this report may be hopeful
with respect to the clinical application of metronomic chemotherapy
with sorafenib for advanced HCC. Iwamoto et al. [116] demonstrated
that metronomic chemotherapy with S-1 inhibited tumor growth and
prolonged survival of hepatoma tumor–bearing mice and that these
effects were enhanced by the addition of vandetanib, an oral inhibitor
of both the epidermal growth factor receptor and VEGFR-2. The anti-
tumor effects of metronomic chemotherapy with S-1 alone were shown
to be mediated mainly through inhibition of angiogenesis by up-
regulation of TSP-1 expression and direct inhibition of endothelial cell
proliferation in tumor tissues. With regard to the toxic effects of such
therapies, the use of MTD S-1 caused body weight loss and myelo-
suppression, whereas S-1 metronomic chemotherapy or S-1 metro-
nomic chemotherapy with vandetanib did not cause any severe
toxicity. Metronomic chemotherapy with a single agent did not cause
an antitumor effect in one study by Tang et al. [111]. However, not
only S-1 metronomic chemotherapy with vandetanib but also metro-
nomic S-1 monotherapy caused significant antitumor effects in the
study by Iwamoto et al. Perhaps these differences might be due to
greater antitumor effects caused by S-1 compared with UFT [116],
although the different models could be another explanation.
Jang et al. [117] used a chemically induced model of HCC in rats
and compared an MTD versus metronomic chemotherapy protocol
using cyclophosphamide. The metronomic protocol was more effec-
tive in prolonging survival than the MTD method and also sup-
pressed metastasis formation, not just intrahepatic tumor growth.
Among the mechanisms implicated for the results included suppres-
sion of HIF-1α levels and matrix metalloproteinases (MMPs), includ-
ing MMP-2 and MMP-9, and also of the MMP-2 activator, tissue
inhibitor of metalloproteinase-2 (TIMP-2). In a previous study by the
same group using the rat HCC model, suppression of VEGFR-2 caused
by metronomic cyclophosphamide was also reported [113].
Metronomic Chemotherapy: Clinical Studies
To date, more than 50 clinical trials, mostly phase II trials, of met-
ronomic chemotherapy have been reported in adult patients with
breast cancer, lung cancer, prostate cancer, malignant brain tumor,
colon cancer, multiple melanoma, malignant lymphoma, HCC,
and other types of tumors [118–120]. Many of those clinical trials
included both chemotherapeutic and antiangiogenic agents. About
80% of the trials have reported positive efficacy of metronomic chemo-
therapy. In addition to the improvement in therapeutic response rate
(complete response + partial response) and/or clinical benefit (complete
response + partial response + stable disease), Orlando et al. [121]
showed that 27% of patients with advanced breast cancer who were
already resistant to trastuzumab responded to treatment using doublet
metronomic cyclophosphamide and methotrexate, in combination
with trastuzumab. Furthermore, Kato et al. [122] and Watanabe
et al. [123] reported that continuous daily administration of nontoxic
doses of UFT was safe and effective as postoperative adjuvant treatment
in randomized phase III adjuvant trials undertaken in patients with
non–small cell lung cancer and breast cancer, respectively. UFT was
administered daily with no breaks for 2 years and can be viewed as a
Table 1. Preclinical Studies Evaluating Metronomic Chemotherapy Regimens in Rodent Models of HCC.
Animal Model Drug Used Reference
Human HCC cell line orthotopic xenografts in SCID mice Oral UFT + cyclophosphamide plus sorafenib or DC101 Tang et al. [111]
Human HCC cell line orthotopic xenografts in SCID mice Oral UFT + sorafenib Tang et al. [114]
Human HCC cell line orthotopic xenografts in nude mice Intravenous doxorubicin plus bevacizumab Zhou et al. [115]
Chemically induced HCC in rats Oral cyclophosphamide Park et al. [113]
Chemically induced HCC in rats Cyclophosphamide Jang et al. [117]
Human HCC cell line subcutaneous xenografts in nude mice Oral S-1 + vandetanib Iwamoto et al. [116]
Human HCC cell line xenografts and primary HCC cells from
patients in Nonobese diabetic/SCID/interleukin-2 (IL-2) receptor γ null mice
Oral cyclophosphamide Martin-Padura et al. [67]
SCID indicates severe combined immunodeficiency.
S-1 is an oral 5-FU prodrug; UFT is an oral 5-FU prodrug; vandetanib is an oral tyrosine kinase inhibitor that targets VEGFRs and epidermal growth factor receptors; DC101 is an anti-mouse VEGFR-2
neutralizing monoclonal antibody.
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metronomic chemotherapy-like trial. In contrast, a few other clinical
trials of metronomic chemotherapy reported negative outcomes. In
particular, malignant brain tumors seem to be resistant to metronomic
chemotherapy [124–127]. With regard to adverse effects, metronomic
chemotherapy was associated with minimal toxicity and severe adverse
events are rare. The most common mild side effects were nausea,
vomiting, fatigue, and bone marrow suppression [128,129]. In view
of the encouraging preclinical and clinical findings evaluating metro-
nomic chemotherapy or metronomic chemotherapy combined with
targeted agents—especially antiangiogenic drugs—a number of random-
ized phase III trials have been initiated, four in breast cancer and two in
colorectal cancer (www.clinicaltrials.gov) [130]. Two are adjuvant trials.
The chemotherapy drugs involved include cyclophosphamide, metho-
trexate, and capecitabine, and the antiangiogenic drug, when used, is
bevacizumab (Avastin), the monoclonal anti-VEGF antibody.
Metronomic Chemotherapy: Clinical Setting
of HCC
To date, there are only four clinical trials evaluating metronomic
chemotherapy for HCC (Table 2). One reported negative result,
whereas others reported positive natures. Treiber et al. [131] randomly
classified 38 patients with advanced HCC into the following four treat-
ment groups: patients of group 1 received 30mg of octreotide on day 1,
group 2 received octreotide on day 1 and 400 mg of imatinib daily,
group 3 received oxaliplatin (60-90 mg/m2) on day 1, and group 4
received oxaliplatin (20-30 mg/m2) on days 1, 8, and 15 combined
with 30 mg of octreotide on day 1 and 400 mg of imatinib daily.
The time to progression and overall survival were not different among
the groups in this phase I/II trial. Hsu et al. [132,133] conducted
another phase II study of the combination of sorafenib (400 mg twice
daily) with metronomic UFT (125 mg/m2 based on tegafur twice
daily) for advanced HCC. They evaluated the efficacy and safety
in 53 patients with Child-Pugh class A. The median progression-
free survival was 3.7 months, and median survival was 7.4 months.
Four patients showed partial response and 26 had stable disease.
Treatment was associated with some severe toxicity including fatigue
(15%), abnormal liver function (13%), elevated serum lipase (10%),
hand-foot skin reaction (9%), and bleeding (8%). The authors
concluded that metronomic chemotherapy with UFT could be safely
combined with sorafenib and that such combination could improve the
efficacy of sorafenib in patients with advanced HCC when compared to
previous reports in similar patient cohorts treated with sorafenib alone
[28,134]. The concurrent use of metronomic chemotherapy and sora-
fenib might augment antitumor efficacy but without a high incidence
of severe side effects. Woo et al. [135] reported the results of a phase II
trial involving infusion of metronomic epirubicin with cisplatin and
5-FU and found it to be a safe and potentially useful treatment for
HCC patients with portal vein thrombosis (MST; 162 days). In
addition, Shao et al. [136–138] undertook a metronomic UFT plus
thalidomide, sorafenib, or bevacizumab trial in patients with advanced
HCC and observed it to be safe, demonstrating modest activity (MST;
4.8 months). There are also two case reports reporting encouraging
results in individual HCC patients treated with metronomic capecita-
bine [139,140]. In addition, Allegrini et al. [141] reported that metro-
nomic UFT and cyclophosphamide plus celecoxib in heavily pretreated
gastrointestinal patients including two patients with HCC were well
tolerated and associated with interesting activity. To confirm the thera-
peutic efficacy and safety of metronomic chemotherapy in patients with
advanced HCC, more (randomized) phase II trials with other anti-
cancer agents and molecular targeted agents, including randomized
controlled trials in larger populations, will be required.
Conclusions
In this review, we have attempted to outline the many reasons why
we feel metronomic chemotherapy, especially when used in conjunc-
tion with an antiangiogenic drug such as sorafenib, is a potentially
promising strategy to consider for the treatment of patients with
advanced HCC. In summary, these reasons are given as follows:
1. HCC is a highly angiogenic tumor, driven by such proangiogenic
growth factors such as VEGF and bFGF.
2. Sorafenib is already approved for treatment of patients with
HCC.
Table 2. Clinical Studies Evaluating the Therapeutic Efficacy of Metronomic Chemotherapy in Patients with HCC.
Drugs Used Results/Comments References
Octreotide, imatinib, oxaliplatin Phase I/II study. Metronomic chemotherapy with oxaliplatin in combination with
antiangiogenic drugs suppressed the increase of serum E-selectin,
VEGF-A, PDGF-BB, and α-fetoprotein levels.
Treiber et al. [131]
UFT, sorafenib Phase II study. Metronomic chemotherapy with UFT was safely combined with
sorafenib and showed activity to improve the efficacy of sorafenib.
Hsu et al. [132]
5-FU, sorafenib, bevacizumab, thalidomide Phase II study. An early α-fetoprotein response was a useful surrogate marker to
predict treatment efficacy and prognosis of metronomic chemotherapy with
5-FU in combination with antiangiogenic agents.
Shao et al. [136]
Capecitabine Case report. Metronomic chemotherapy with capecitabine induced
complete remission with minimal toxicity.
Brandi et al. [140]
Capecitabine Case report. Metronomic chemotherapy with capecitabine for HCC patient with
Child-Pugh class B was effective and well tolerated.
Ballardini et al. [139]
UFT, sorafenib Phase II study. Vascular response measured by dynamic contrast-enhanced
MRI predicted tumor response and survival by metronomic UFT therapy with sorafenib.
Hsu et al. [133]
UFT, sorafenib Phase II study. High baseline circulating EPC levels were associated with
poor prognosis by sorafenib and metronomic chemotherapy with UFT.
Shao et al. [138]
Epirubicin, cisplatin, 5-FU Prospective study. Metronomic chemotherapy might be a safe and
useful palliative treatment for HCC patients with major portal vein tumor thrombosis.
Woo et al. [135]
UFT, thalidomide Phase II study. High baseline IL-6 and IL-8 levels were associated with poor prognosis.
Metronomic chemotherapy with UFT and thalidomide was safe and demonstrated modest activity.
Shao et al. [137]
MRI indicates magnetic resonance imaging.
UFT is an oral 5-FU prodrug.
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3. Antiangiogenic drugs can augment the efficacy of metronomic
chemotherapy and vice versa, as shown in a very large number of
diverse preclinical studies—especially those involving treatment
of mice with advanced metastatic disease—and also as sug-
gested, or shown, in a number of phase II clinical trial results
of other types of cancer.
4. Metronomic chemotherapy, which functions more as a biologic
therapy, is now known to involve multiple mechanisms that
include antiangiogenesis and antivasculogenesis, immune
stimulation, and possibly some direct tumor cell targeting ef-
fects, including of the cancer stem cell subpopulation.
5. There is no effective standard chemotherapy for HCC when
using conventionalMTD treatment protocols, and in part, this is
related to the toxicity of such treatments in patients with HCC
who have the underlying comorbidity of liver cirrhosis; in con-
trast, the less toxic regimens associated with metronomic che-
motherapy and the different cellular targets and mechanisms
of action involved may make this an attractive and alternative
type of chemotherapy to consider, especially for treatment of
advanced HCC, but perhaps also for postsurgical adjuvant treat-
ment of early-stage HCC, given the successes of metronomic-
like protocol of UFT reported in adjuvant phase III breast and
lung cancer trials.
6. The total number of preclinical studies showing impressive
results using metronomic chemotherapy-based protocols, espe-
cially in conjunction with antiangiogenic drugs (even in models
of advanced metastatic disease) along with the number of
promising clinical study and trial results that have been pub-
lished to date, argues strongly for giving more consideration
to testing more extensively this type of treatment strategy for
advanced HCC.
7. Some limited preliminary results of several preclinical HCC
studies using metronomic chemotherapy in conjunction with
antiangiogenic drugs indeed suggest that this treatment strategy
can be highly active and, as such, should be given proactive
clinical consideration.
Perspective for Future Directions
In unresectable advanced HCC (BCLC stage C), sorafenib is recom-
mended as the standard treatment. As HCC is usually accompanied
with liver cirrhosis, a combination treatment with less adverse events
will be required to improve the survival benefit of sorafenib. Metro-
nomic chemotherapy will be a candidate treatment that meets these
criteria. To confirm the synergy of metronomic chemotherapy, pro-
spective trials of metronomic chemotherapy with sorafenib compared
with sorafenib alone as the control arm will be necessary as soon
as possible.
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